Arcus Biosciences Inc (RCUS)
16.75
+0.29
(+1.76%)
USD |
NYSE |
Nov 08, 10:41
Arcus Biosciences Revenue (TTM): 263.00M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 263.00M |
| June 30, 2024 | 247.00M |
| March 31, 2024 | 237.00M |
| December 31, 2023 | 117.00M |
| September 30, 2023 | 120.00M |
| June 30, 2023 | 121.00M |
| March 31, 2023 | 119.00M |
| December 31, 2022 | 112.00M |
| September 30, 2022 | 432.62M |
| June 30, 2022 | 409.08M |
| March 31, 2022 | 391.54M |
| December 31, 2021 | 383.00M |
| September 30, 2021 | 38.35M |
| Date | Value |
|---|---|
| June 30, 2021 | 93.42M |
| March 31, 2021 | 85.71M |
| December 31, 2020 | 78.00M |
| September 30, 2020 | 77.78M |
| June 30, 2020 | 15.00M |
| March 31, 2020 | 15.00M |
| December 31, 2019 | 15.00M |
| September 30, 2019 | 6.812M |
| June 30, 2019 | 9.353M |
| March 31, 2019 | 8.853M |
| December 31, 2018 | 8.353M |
| September 30, 2018 | 8.041M |
| June 30, 2018 | 3.913M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
15.00M
Minimum
Dec 2019
432.62M
Maximum
Sep 2022
168.52M
Average
118.00M
Median
Revenue (TTM) Benchmarks
| Merck & Co Inc | 63.17B |
| Intra-Cellular Therapies Inc | 612.78M |
| Syndax Pharmaceuticals Inc | -- |
| Clearside Biomedical Inc | 7.524M |
| Janux Therapeutics Inc | 15.13M |